| DRUG WATCH |
|
| Year : 2013 | Volume
: 45
| Issue : 3 | Page : 298-300 |
Severe skin rash with lamivudine in HIV infected patients: Some unusual case reports
Dolanchampa Modak, Subhasish Kamal Guha
Department of Tropical Medicine, School of Tropical Medicine, Kolkata, West Bengal, India
Correspondence Address:
Dolanchampa Modak
Department of Tropical Medicine, School of Tropical Medicine, Kolkata, West Bengal
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.111906
Lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI) licensed for as a first line drug in Human immunodeficiency virus (HIV) infection and also in the treatment of hepatitis B. It is relatively nontoxic in nature and potentiates the antiviral effects of other NRTIs like zidovudine. Although lamivudine is well-tolerated, certain dermatological side effects like severe skin rash may appear. We report a case series of severe skin rashes in four HIV-infected patients, probably due to lamivudine.
[FULL TEXT] [PDF]*
|
